Who is sponsoring NCT03048058?

NCT03048058 is sponsored by Wake Forest University Health Sciences.

What drugs are being tested in NCT03048058?

Interventions: brimonidine topical gel 0.33% & survey, brimonidine topical gel 0.33% & SOC.

What is the status of NCT03048058?

NCT03048058 is currently COMPLETED.

Last reviewed 2018-09-10 · How we verify

Internet Surveys and Their Impact on Adherence and Quality of Life to Mirvaso for Rosacea

NCT03048058 Phase 4 COMPLETED Results posted

An investigator-blinded, prospective, 6 month study of subjects with persistent erythema associated with active rosacea will be conducted in 20 subjects aged 18 years and older. All subjects will receive standard-of-care brimonidine topical gel, 0.33% with instructions to apply it once daily per package insert. Adherence will be assessed using weekly internet surveys to document how often the medication is being used, as well as reminders about rosacea triggers and general use of brimonidine.

Details

Lead sponsor	Wake Forest University Health Sciences
Phase	Phase 4
Status	COMPLETED
Enrolment	20
Start date	2016-05-05
Completion	2017-06

Conditions

Rosacea

Interventions

brimonidine topical gel 0.33% & survey
brimonidine topical gel 0.33% & SOC

Primary outcomes

Adherence (% of Prescribed Doses That Were Actually Taken by the Subject) — 6 months
To assess adherence to topical brimonidine for the treatment of rosacea as measured by MEMS caps. The result will be the % of prescribed doses that were actually taken by the subject

Countries

United States